1. Subcutaneous amivantamab combined with lazertinib was non-inferior to intravenous amivantamab with lazertinib in terms of efficacy in treating refractory...

1. Daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) as induction and consolidation therapy led to superior progression-free survival...

1. Asciminib demonstrated higher efficacy for the treatment of newly diagnosed CML than imatinib and second-generation TKI 2. Asciminib had...

1. A decision support system using the Molecular International Prognostic Scoring System (IPSS-M) can optimize the timing of HSCT for...

1. Achieving Minimal Residual Disease (MRD) negativity at baseline before lenalidomide maintenance, and at one-year post Auto-HCT (AutoHCT) predicts increased...

1. Lymphoid malignancy survival rates in European countries correlate with national health expenditure level. 2. Geographic disparities in lymphoid malignancy...

1. Mitoxantrone enhances five-year event-free survival over liposomal daunorubicin in MRD-guided pediatric AML treatment. 2.High-risk patients identified by MRD guidance...

1. Pazopanib did not improve disease-free survival in post-metastasectomy renal cell carcinoma patients 2. There was a concerning trend favouring...

1. VENICE-1 observed high response rates (complete or partial remission) in both BCRi-naïve and BCRi-pretreated patients with refractory or relapsed...

1. Tabelecleucel provided clinical improvement in patients with EBV-related post-transplant lymphoproliferative disease. 2. There were no fatal treatment related adverse...